Outcomes Data of Adipose Stem Cells to Treat Osteoarthritis

Last updated: August 28, 2018
Sponsor: StemGenex
Overall Status: Active - Recruiting

Phase

N/A

Condition

Osteoarthritis

Treatment

N/A

Clinical Study ID

NCT02241408
SVF01OA
ASCOA-01
  • Ages > 18
  • All Genders

Study Summary

The purpose of this study is to determine the impact that treatment with a cellular concentrate derived from an individual's own fat, known as the stromal vascular fraction (SVF), has on joint pain and functionality in people with Osteoarthritis (OA). SVF contains components with "regenerative" properties, including stem cells that have shown promise for ameliorating specific disease conditions. This study is designed to evaluate joint pain and functionality changes in individuals with OA for up to 12 months following SVF treatment.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Fluent in English

  • Over the age of 18

  • Diagnosed with OA of the knee and/or hip

  • Scheduled for intravenous and intra-articular administrations of autologous SVF

  • Capable of understanding and willing to sign informed consent

  • Willing and able to complete brief phone interviews

  • Willing and able to complete online surveys

Exclusion

Exclusion Criteria:

  • Co-morbidity with an autoimmune disorder

  • Pregnant, may become pregnant, or breastfeeding

  • Subjects for which baseline data is not available

Study Design

Total Participants: 100
Study Start date:
September 01, 2014
Estimated Completion Date:
September 30, 2019

Connect with a study center

  • StemGenex

    La Jolla, California 92037
    United States

    Site Not Available

  • StemGenex

    San Diego, California 92121
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.